Top 10 pharma companies in India (2022)

Pharma companies has faster-growing markets and the largest exporter of drugs by volume. The Indian pharmaceutical industry is the world’s third largest in terms of volume and ranks 11th in terms of value.

The Indian pharmaceutical market recorded ~9.5% CAGR between 2016-20 to reach US$21 Billion. It is
expected to grow at 7.5-10.5% CAGR to US$28-32 Billion by 2025.

we can view the list of pharma in India market has placed their performance for the growth of Indian pharma market.

Now we have analysis the company based on their revenue and the company has placed their position in the result of FY22.

1. Sun Pharmaceutical Industries Limited

• Founded: 1983
• Headoffice: Mumbai
• Listed in Exchange: NSE(SUNPHARMA), BSE(524715)
• Industry: PHARMACEUTICALS
• website: sunpharma.com/india/
• Sun pharma contact details: PH: (+91 22) 4324 4324
• Sun parma Product list

Sun pharma company profile:

Sun Pharmaceutical Industries Limited is popularly known as Sun Pharma, they are the fourth largest specialty generic pharmaceutical company in the world based on revenue.

Sun Pharma has manufacturing high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.

They are a leading specialty generics pharmaceutical company with a strong presence in India and the US markets. It is also amongst one of the leading Indian pharma companies in emerging markets.

Sun Pharma has manufacturing capabilities for a variety of dosage forms, such as injectables, sprays, ointments, creams, liquids, hormones, drug delivery systems, tablets, and capsules.

Sun Pharmaceutical Industries Limited is a public limited company incorporated and domiciled in India. Sun pharma is listed on the BSE Limited and NSE Limited.

Sun pharma Financial Analysis:

• FY22: Nine-month statement
  • Revenue from operation: 290,403.4 million
  • Profit before tax: 65,569.2 million
  • Profit of year: 55,499.8 million

The Key ratio of Sun pharma

• Return on Net Worth (%): 6.2%
• Debtors Turnover: 3.7
• Inventory Turnover: 1.0
• Interest Coverage Ratio: 51.2
• Current Ratio: 1.9
• Debt Equity Ratio: 0.08
• Operating Profit Margin (%): 24.5%
• Net Profit Margin (%): 8.8%

2. Dr. Reddy’s Laboratories Limited

• Founded: 1986
• Headoffice: Telangana
• Listed in exchange: NSE(DRREDDY), BSE(500124)
• Industry: PHARMACEUTICALS
• website: www.drreddys.com
• Market Cap (₹ Lakhs): 70,04,426.42
• Contact details: +91 22 6280 1219, +91 22 7115 8120

Dr. Reddy’s laboratories company profile:

Dr. Reddy’s laboratory is formally known as Dr.Reddy and they are an integrated pharmaceutical company globally and manufacturing, sales, and marketing operations span over 56 countries.

Dr.reddy business offers a portfolio of products and services that included Global Generics, Biologics, Active Pharmaceuticals Ingredients, Aurigene Pharmaceuticals services.

Dr.Reddy has focused on innovation-led affordability gives customers access to the most complex active ingredients, while maintaining a consistent global quality standard.

Dr.reddy had 52 subsidiaries and one joint venture company

• Dr.reddy top 3 product manufacturing and services provider are
  • uprenorphine & Naloxone,
  • Omeprazole and
  • Nimesulide
• For Product details use the link drreddys.com/our-products/business-focus/
• Dr.reddy have 18 manufacturing units and six research and development facilities in India.
  • API Facilities there are 4 plant in Telugana and 2 in Andra Pradesh,
  • Formulation facilities there are 12 plants in Telugana, Andra Pradesh, Himachal Pradesh,

Dr.reddy Financial details:

FY22: Nine-month statement

• Revenuefrom operation:160,023 million
• Profit before tax: 29,815 million
• Profit of the year: 22,693 million

The key ratio of Dr.reddy

• Net Debt/Equity: 0.04
• Current Ratio: 1.8
• Net Profit Margin: 9.1%
• Return on Net Worth: 10%

3. Cipla Limited

• Founded: 1935
• Headoffice: Mumbai
• Listed in Exchange: NSE(CIPLA), BSE(500087)
• Industry: PHARMACEUTICALS
• website: www.cipla.com

Cipla company profile:

Cipla Limited is one of the top API pharma companies in globally. In India, Cipla is involved in its business comprises branded prescription drugs, trade generics, and consumer health products.

Cipla Stand for Chemical Industrial & Pharmaceutical Laboratories Ltd and for Cipla product use the link https://www.cipla.com/our-offerings

Cipla’s product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.

50 years in manufacturing APIs, Cipla has produced more than 200 generics and complex APIs. Cipla’s dedicated 300+ strong team of scientists enable the Company to capably handle a wide range of chemistries and complex molecules.

Cipla Financial analysis:

FY22 Nine-month statement:

• Revenue from operation: 16,399.42 crores
• Profit before tax: 3,170.06 crores
• Profit of the year: 2,154.68 crores

The key ratio of Cipla:

• Net Debt to EBITDA: -0.45
• Net Debt to Equity: (-0.10)
• Interest Coverage Ratio: 27
• Return on Equity (RoE): 14.1 %
• Earning per share: ₹ 26.71

4. Aurobindo Pharma Limited

• Founded: 1986
• Headoffice: Hyderabad 
• Listed in Exchange: NSE(AUROPHARMA), BSE(524804)
• Industries: PHARMACEUTICALS
• website: www.aurobindo.com

Aurobindo Pharma company profile:

Aurobindo Pharma Limited is formally known as Aurobindo Pharma. they are a leading global API pharma companies and manufacturing generic formulations and Active Pharmaceutical Ingredients (API).

Aurobindo pharma has 27 manufacturing and packing facilities for its API and formulations business, which has the requisite approval from global regulatory authorities such as US FDA, EDQM, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil, etc.

Especially in APIs has 11 high specification manufacturing plants approved by key regulators and equipped with a site dedicated control laboratories in India.

Aurobindo pharma has one of the largest R&D facilities and capabilities across five research centres in India and three R&D centres in the US.

Our in-house R&D drives rapid filing of Drug Master Files (DMFs), Abbreviated New Drug Applications
(ANDAs) and formulations dossiers worldwide. We are among the largest filers of DMFs and ANDAs with the USFDA.

Aurobindo pharma Financial analysis:

FY22: Nine-month statement

• Revenue from operation: 17,64,612 lakhs
• Profit before tax: 2,77,911 lakhs
• Profit of the year: 2,07,097 lakhs

Key ratio:

• Net debt to Equity: (0.04)
• Return on Equity (ROE): 7.5
• Net debt to EBITDA:(0.15)
• Earnings per share: 23%

5. Divi’s Laboratories Limited

• Founded: 1990
• Headoffice: Telangana
• Listed in Exchange: NSE(DIVISLAB), BSE(532488)
• Industry: PHARMACEUTICALS
• website: www.divislabs.com
• Market Cap (₹ Lakhs): 1,11,88,173.30
• contact number: +91 (40) 6696 6300, +91 (40) 2378 6300

Divi’s Laboratories company profile:

Divi’s Laboratories Limited is a leading manufacturer of API pharama companies in India and intermediates as well as nutraceutical ingredients offering quality products with a high level of compliance to customers in over 95 countries.

Divi has six multi-purpose manufacturing facilities from two sites with all support infrastructure like utilities, environment management, and safety systems.

Divi has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi’s
Laboratories Europe AG in Switzerland for marketing its nutraceutical products and to provide a greater reach to customers within these regions.

Divi’s product portfolio comprises two broad categories

1. Generic APIs (Active Pharma Ingredients) and Nutraceuticals
2. Custom Synthesis of APIs, intermediates and specialty ingredients for innovator pharma giants.
3. Divi’s product list use the link: www.divislabs.com/api-manufacturer-world/active-pharmaceutical-ingredients/generic-api-products/

Divi”s Financial analysis:

FY22: Nine-month statement

• Revenue from operation: 644139 lakhs
• Profit before tax: 260776 lakhs
• Profit of the year: 206581 lakhs

The key ratio of Divi’s Laboratories

• Return on Net Worth(%): 21.08%
• Return on Capital Employed (%): 34.69%
• Basic EPS: 73.63
• Debtors Turnover: 4.19
• Inventory Turnover: 3.62
• Current ratio: 5.63
• Debt Equity ratio: 0.00004
• Operating profit margin (%): 42.02%
• Net profit margin (%): 28.49%

6. Alkem Laboratories Limited

• Founded: 1973
• Headoffice: Mumbai
• Listed in exchange: NSE(ALKEM), BSE(539523)
• Industry: Pharmaceutical
• website: www.alkemlabs.com
• Contact Number: (022) 3982 9999

Alkem Laboratories Ltd company profile:

Alkem Laboratories is a leading Indian generic pharmaceutical company in India. They were popularly known as Alkem. They develops, manufactures, and sells pharmaceutical and nutraceutical products in India and overseas.

Alkem has a strong position in India pharma market and been ranked in top 10 companies in India, With a broad portfolio of more than 800 brands and a highly proficient management team.

Alkem is one of the prominent names in India in the acute therapy areas of Anti-infective, Gastro-intestinal, Pain management and Vitamins/ Minerals/ Nutrients products

They had 20 state-of-the-art manufacturing facilities that are approved by various regulatory agencies like the US FDA, World Health Organization (WHO), MHRA (UK), TGA (Australia), ANVISA (Brazil),
and MCC (South Africa) and 6 R&D centres across multiple locations in India and the United States.

Alkem Financial position:

• Reveneue from operation:
• Profit before tax:
• Profit of the year:

The key ratio of Alkem lab

• Debtors Turnover: 5.43
• Inventory Turnover: 1.51
• Interest Coverage Ratio: 28.31
• Return on Net Worth: 21.5%
• Debt to Equity Ratio: 0.20
• Current Ratio: 1.92

7.Gland Pharma Limited

• Founded:1978
• Headoffice: Hyderabad 
• Listed in Exchange: NSE(GLAND), BSE(543245)
• Industry: Pharmaceuticals 
• Website: www,glandpharma.com
• Market capitalization: 55,04,141.22 lakhs
• Contact number:+91-40-30510999 | +91-8455-699999 |+91-7075736524

Gland Pharma company profile:

Gland Pharma is one of the fastest-growing generic injectables-focused and API pharma companies in India. they offer services that cover the entire injectables value-chain, including contract development, own development, dossier preparation and filing, technology transfer, and manufacturing across a range of delivery systems.

Gland Pharma has made substantial investments in its manufacturing infrastructure, with 8 manufacturing facilities in Southern India, comprising of 4 finished formulations facilities with a total of 23 production lines and four API facilities.

Gland Pharma sells its products primarily under a business-to-business (“B2B”) model in over 60 countries with its core markets being the United States, Europe, Canada, Australia, and India. For Product use the link: glandpharma.com/our_business/product

Gland Pharma Financial analysis:

FY22: for the nine-month statement

• Revenue from operation: 32,976.94 million
• Profit before tax: 12,380.68 million
• Profit of the year: 9,257.62 million

The key ratio of Gland Pharma

• Debtors turnover 5.16
• Inventory turnover 1.58
• Current ratio 4.13
• EBITDA margin 40%
• Net profit margin 28%
• Return on net worth 17%

8. Torrent Pharmaceuticals Limited

• Founded: 1959
• Headoffice: Gujarat
• Listed in Exchange: NSE(TORNTPHARM), BSE(500420)
• Industry: Pharmaceuticals
• website: torrentpharma
• Contact number: +91-79-26599000

Torrent Pharmaceuticals Company profile:

Torrent Pharmaceuticals is one of the leading pharma companies in India. They were popularly known as Torrent Pharma and the flagship company of the Torrent Group.

Torrent Pharma continues to emphasise on chronic therapies as its main area of focus and hopes to continue gaining market share in key sub-therapies. Torrent Pharma has seen a rank improvement across anti-diabetic, derma and gynecology therapy areas.

Torrent Pharma has launched several brand extensions with first-in-India combinations, Some important new introductions in key markets were – Dapagliflozin and Rivaroxaban in the CVD therapeutic area; Brivaracetam in the CNS segment; Obeticholic Acid within the Gatro-intestinal therapy along with strengthened presence in Pain Analgesic segment through NDDS Tapentadol Nasal Spray.

Torrent Pharma financial position:

• Revenue from operation: 5,017 crores
• Profit before tax: 1,121 crores
• Profit of the year FY22: 770 crores

Key ratio of Torrent pharma

• Operating Profit Margin 32%
• Net Profit Margin 16%
• Return on Net Worth 21%
• Debtors Turnover (days): 71
• Inventory Turnover (days): 124
• Interest Coverage: 6.21
• Debt/equity: 0.71
• Current Ratio: 1.13

9. Glenmark Pharmaceuticals Limited

• Founded: 1977
• Headoffice: Mumbai
• Listed in Exchange: NSE(GLENMARK), BSE(532296)
• Industry: Pharmaceuticals
• Website: glenmarkpharma
• Market capitalization: 55,04,141.22 lakhs

Genmark Pharmaceuticals company profile:

Glenmark Pharmaceuticals is a global, integrated, innovation-led API pharma companies, with a presence in the world’s major markets.

Genmark reorganized itself into three different entities: Glenmark Pharmaceuticals, Glenmark Life Sciences and Ichnos Sciences. This restructuring is expected to place all three companies on an accelerated growth trajectory.

Glenmark is one of the fastest-growing companies in the Indian Pharma market. The launch of innovative and differentiated products with successful brand building helped to reach 14 positions in the Indian pharma.

Nine of our brands are amongst the ‘Top 300 Brands’ in the Indian Pharmaceutical Market. This is the result of our focus on launching differentiated products in core areas, effectively utilizing our product selection, R&D, manufacturing skills, and extended reach through a strong sales force and market network.

Glenmark Pharmaceutical financial analysis:

FY22: Nine-month statement

• Revenue from operaation: 1857 crores
• Profit before tax: 1172
• Profit of the year: 787 crores

10. IPCA Laboratories Limited

• Founded: 1949
• Headoffice: Mumbai
• Listed in Exchange: NSE(IPCALAB), BSE(524494)
• Industry: Pharmaceutical
• website: ipca
• Market capitalization: 23,52,218.66 lakhs

IPCA Laboratories company profile:

IPCA Laboratories is a global API pharma companies, with creating healthy doses of life. IPCA is one of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally.

IPCA has produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

they have 15 APIs & 11 Formulations manufacturing facilities across the globe and top leading brands in Pain, Rheumatology, Antimalarials, and Haircare therapy in India

IPCA has branded formulations business in India now comprises of 16 marketing divisions focusing on key therapeutic segments with a portfolio of about 145 brands.

IPCA Laboratories financial statement:

FY22: Nine-month statement

• Revenue from operation: 4230.91 crores
• Profit before tax: 950.73 crores
• Profit of the year: 760.53 crores

The key ratio of IPCA

• Operating profit margin (%): 25.1%
• Net profit margin (%): 21.93%
• Debtors turnover ratio: 6.30
• Current ratio: 3.08
• Inventory turnover ratio: 2.77
• Debt Equity Ratio: 0.03
• Return on Net Worth (%): 24%